Pulmonary Arterial Hypertension (PAH) Therapeutics

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
342
Pulmonary Arterial Hypertension (PAH) Therapeutics 2015-2022 - Global Strategic Business Report 2018

Dublin, July 11, 2018 (GLOBE NEWSWIRE) -- The "Pulmonary Arterial Hypertension (PAH) Therapeutics - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2015 through 2022. Also, a six-year historic analysis is provided for these markets. This report analyzes the worldwide markets in US$ Million. The global market is analyzed by the following Drug Class and Brands:

  • Endothelin Receptor Antagonist (Letairis/Volibris, Macitentan, Thelin, & Tracleer)
  • Prostacyclin and Prostacyclin Analogs (Epoprostenol/Veletri*, Flolan, Remodulin, Selexipag, Tyvaso, Ventavis, & Orenitram)
  • PDE-5 Inhibitors (Cialis/Adcirca, & Revatio)
  • Soluble Guanylate Cyclase (sGC) Stimulator (Riociguat)

The report profiles 31 companies including many key and niche players such as:

  • Actelion Pharmaceuticals Ltd (Switzerland)
  • Bayer AG (Germany)
  • Gilead Sciences, Inc. (US)
  • Pfizer, Inc. (US)
  • United Therapeutics Corporation (US)
  • Lung Biotechnology PBC (US)

Key Topics Covered

1. INDUSTRY OVERVIEW Pulmonary Arterial Hypertension (PAH) A Prelude Current & Future Analysis PAH Drugs Market by Class The PAH Classification PH Patient Groupings as per World Health Organization Classification of PAH patients as per New York Heart Association (NYHA) Oral Therapies lead the Global PAH Therapeutics Market Combination Therapy Favored over Monotherapy for PAH Pediatric PAH A Potential Market with Unmet Need Inflammation: New Target for PAH Therapeutics Aging Population & PAH 2. COMPETITIVE SCENARIO Leading Players Leading Approved Drugs as Per Mode of Administration Major Drug Brands by Class Prostacyclin receptor agonist/ Prostacyclin Analogue Flolan (Epoprostenol) Ventavis (Iloprost) Remodulin (Treprostinil) Orenitram Tyvaso Uptravi (Selexipag) Veletri (Epoprostenol for Injection) Phosphodiesterase 5 inhibitor Revatio Adcirca (Tadalafil) Endothelin receptor antagonists (ERAs) Opsumit Tracleer (Bosentan) Letairis (Ambrisentan) Loss of Market exclusivity Tones Down Growth Patent Expiry of Leading PAH Drugs Opsumit & Uptravi: Game-changers for Actelion Selexipag Latest Entrant in PAH Therapeutics United Therapeutics A Major Player Gilead Sciences GlaxoSmithKline Bayer 3. PAH PIPELINE Pulmokine Investigates PDGF Receptor Pathway Reata Pharmaceuticals Completes Phase 3 Study for Bardoxolone methyl Eiger BioPharmaceuticals Commences Phase 2 Trials for Bestatin Insmed Investigates INS 1009 LTT Bio-Pharma Focuses on LT-2004 Ascendis Investigates TransCon Treprostinil in a Phase I trial Arena Initiates Phase II Trial for Ralinepeg, TheraSilence nanoparticles Found to Reduce Pulmonary Arterial Thickness CXA-10 to Undergo Phase II Study Atu111 Undergoes Preclinical Trial for PH RP5063 A NCE for PAH SteadyMed to File NDA for Trevyent Pluristem's PLX-PAD Sagene Pharmaceuticals, Inc. Select PAH Therapeutics under Pipeline: 2016 4. PRODUCT OVERVIEW 5. PRODUCT INNOVATIONS & APPROVALS Nippon Shinyaku Receives Marketing Approval for Uptravi Actelion to Initiate Phase III Study for Pediatric Formulation of Opsumit Actelion Announces USFDA Approval of Uptravi Reata Pharmaceuticals' Bardoxolone Methyl Receives Orphan Drug Designation Actelion Receives Approval for Opsumit from Japan's MHLW Bayer Healthcare Receives Approval for Adempas from Japan's MHLW Silence Therapeutics Develops Gene Toolkit for PAH Research Arena Pharmaceuticals' APD811 Receives Orphan Drug Status for PAH Treatment Bayer's Adempas Approved for Two Rare Types of PAH Actelion's Opsumit Receives Approval from Australia's TGA 6. RECENT INDUSTRY ACTIVITY Arena Pharmaceuticals Initiates Phase 2 Clinical Trial for Ralinepag Gilead Reports Top-Line Phase 2 Results for GS-4997 ( Selonsertib) in Pulmonary Arterial Hypertension (PAH) Gilead Sciences Accelerates its PAH Portfolio Mallinckrodt Pharmaceuticals Acquires Ikaria Supernus Pharmaceuticals Receives US$2 million Milestone Payment from United Therapeutics Vectura Group plc Acquires Activaero GmbH Mast Therapeutics Completes Acquisition of Aires Pharmaceuticals 7. FOCUS ON SELECT GLOBAL PLAYERS Actelion Pharmaceuticals Ltd (Switzerland) Bayer AG (Germany) Gilead Sciences, Inc. (US) Pfizer, Inc. (US) United Therapeutics Corporation (US) Lung Biotechnology PBC (US) 8. GLOBAL MARKET PERSPECTIVE Total Companies Profiled: 31 (including Divisions/Subsidiaries 33)

  • The United States (18)
  • Japan (3)
  • Europe (10)
    • France (1)
    • Germany (3)
    • The United Kingdom (3)
    • Rest of Europe (3)
  • Asia-Pacific (Excluding Japan) (1)
  • Middle East (1)

For more information about this report visit https://www.researchandmarkets.com/research/h...onary?w=12

CONTACT: ResearchAndMarkets.com Laura Wood, Senior Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 Related Topics: Cardiovascular Drugs

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Moore, Schulman & Moore Attorneys Earn Top Honors Again

Updated Category News Views 4

In the realm of family law, consistency in excellence matters just as much as landing a high-stakes stock trade. Moore, Schulman & Moore, APC, a San Diego family law outfit, has grabbed the spotlight yet again with nine of its ace attorneys snagging recognition from the 2027 Super Lawyers roster. A Tradition of Professional Recognition Leading the pack is Erik Moore, a...

Continue Reading
Ingram Mercantile's Aviation Push: SCORE or Sink?

Updated Category News Views 5

Unpacking Neobanx's Strategic Play Straight off the tarmac, Neobanx launches Ingram Mercantile, placing their bets on the aviation sector with none other than Eli Stepp at the helm. This ain't just another day in the sky for those in the know; it's part of a gutsy bid to inject some high-octane intelligence into the world of retail. I mean, have you seen the landscape...

Continue Reading
Zenni and Chase Stokes Foster Student Wellbeing in NYC

Updated Category News Views 3

Picture this: near 300 high schoolers milling around, glancing through shiny new glasses from the Zenni x Chase Stokes collection. In the heart of New York City, these kids are getting a double-dose of care that's all too rare—free vision screenings paired with mental health support. It's the kind of collaboration that shows you what's possible when a company, an actor,...

Continue Reading
NCICU's Digital Boost for NC Transfer Students

Updated Category News Views 4

New Platform Eases the Transfer Struggle They’ve finally cooked up something good for the college crowd in North Carolina. The NCICU, with the NCCCS, has rolled out a platform called Transfer Pathways to simplify students' path from two-year to four-year schools. This ain't just a tweak—it's backed by a hefty $2 million in grants. Hats off to those...

Continue Reading
Armor Health Strengthens Corrections Care with New Leader

Updated Category News Views 4

Fresh Blood in Correctional Healthcare Talk about stepping up where it counts! Armor Health is shaking things up, bringing in Jill Bromley as their new Regional Behavioral Health Director. The name might not ring any bells for the average Joe, but in the world of correctional healthcare, it’s like they've just upgraded from a sedan to a sports car. Armor’s game here...

Continue Reading
Helio Genomics Shakes Up Liver Cancer Detection Strategy

Updated Category News Views 5

Rethinking Liver Cancer Detection with HelioLiver Sometimes you stumble upon a tech piece that might genuinely shake up the game. Helio Genomics just poured some serious intel at the San Antonio Liver Cancer Symposium, showcasing how their HelioLiver Dx might outgun traditional scans in sniffing out hepatocellular carcinoma (HCC). They threw down four studies revealing...

Continue Reading
Elevest Unveils MADE: Shaping Wealth for Athletes, Artists

Updated Category News Views 4

Turning Talent Into Tangible Wealth Ask any musician or athlete, and they'll tell you—riding those career highs is exhilarating, but financial stability can be a different ballgame. Here comes Elevest Capital with a fresh move meant to set the players right where many falter: long-term ownership. They're rolling out MADE, a new initiative focused on flipping that burst...

Continue Reading
STRATA Showcases Excimer Laser Success in Dermatology

Updated Category News Views 4

The Cutting Edge of Skin Care: STRATA's Spotlight It's not every day you hear about dermatology shaking things up, but STRATA Skin Sciences, Inc. pulled it off with flair at the 2026 Fall Clinical Dermatology Conference in Las Vegas. For 'skin in the game,' these folks are leading the charge with their innovative excimer laser phototherapy approach, shining a fresh light...

Continue Reading
Navigating Career Growth Beyond Job Titles at Webinar

Updated Category News Views 5

Hasn't it ever struck you that job titles often fence people in like some unwanted corral, keeping potential tightly leashed? Well, here's something that might shake up your thoughts a tad. University of Phoenix is teeing up a webinar titled "Beyond The Job Title: Finding Purpose and Recognizing the Value You Bring." Scheduled for October 15, 2026, this is all about...

Continue Reading
Boliden's Q3 2026 Results: What's on the Horizon?

Updated Category News Views 3

Boliden Ready to Reveal Q3 Numbers Mark it down, folks. Thursday, October 29, 2026, is the day when Boliden's big wigs will step up to the plate and lay their cards on the table about the company's performance over the last quarter. If you've got any skin in this mining powerhouse, you'll want a front-row seat—or at least a virtual one if you're dialing in from...

Continue Reading

Top 5 Most Recently Viewed Articles

Caribou Biosciences Faces Securities Fraud Lawsuit Amid Losses

Updated Category News Views 139

Understanding the Lawsuit Against Caribou Biosciences Investors in Caribou Biosciences, Inc. (NASDAQ: CRBU) are currently facing significant challenges due to alleged misleading statements made by the company regarding its performance and product safety. A shareholder has initiated a class action lawsuit aimed at representing those who purchased CRBU securities between...

Continue Reading
BMO's Belsky Predicts Resilience of US Stocks Amid Volatility

Updated Category News Views 496

BMO's Bullish Outlook on US Stocks Brian Belsky, the Chief Investment Strategist at BMO Capital Markets, continues to maintain a positive outlook on US equities, despite the recent fluctuations in the market. His unwavering confidence comes even as the S&P 500 experiences losses in four out of the last five weeks. Belsky highlights that this downturn has been largely...

Continue Reading
How Is Pain and Suffering Calculated in Personal Injury Cases?

Updated Category Personal Finance Views 36

Pain and suffering is generally calculated by considering how an injury affects a person's physical comfort, emotional well-being, daily activities, and overall quality of life. Unlike medical bills or lost wages, these losses do not have a fixed price, so courts and insurance companies look at the nature and severity of the injury, recovery period, and long-term effects...

Continue Reading
Leap Therapeutics Showcases Financial Progress and Updates

Updated Category News Views 262

Leap Therapeutics: Financial Highlights and Updates Leap Therapeutics, Inc. (NASDAQ: LPTX), a prominent biotechnology firm dedicated to developing innovative immuno-oncology solutions, has recently revealed its financial results for the latest fiscal year. The focus today is not just on their financial performance, but also on the progress of their in-development...

Continue Reading
Tech Stocks Struggle Amid Economic Growth Concerns

Updated Category News Views 47

Current Trends Impacting Tech Stocks US tech stocks are facing significant challenges, reflecting broader worries about economic growth and the unpredictable AI market. Notably, Nvidia's shares have seen a considerable drop, highlighting the potential impacts on the technology sector. As a leading player in AI technologies, Nvidia's substantial loss in market value...

Continue Reading